Atai Life Sciences Q2 financial results were released recently, alongside an update on the company’s pipeline progression. So, we figured it would be...
COMPASS Pathways has announced a capital raise of up to $285 million, the largest cash injection the industry has seen in quite some time. The post COMPASS...
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition...
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) released its second-quarter financial results for the period ending June 30, 2023, for the second time....
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed First...
Psychedelic legalization in the US first took place in 2020 when Oregon voted to legalize psilocybin use. Just three years later, an influx of other states...
Christain Angermayer gave some clarification on PCN-101, atai's ketamine program, hinting at new direction for the compound. The post Christian Angermayer...
Atai Life Sciences (NASDAQ: ATAI) reported its second quarter 2023 financial results and provided corporate updates. At this time Atai has no revenue to...
Atai noted it was exploring strategic options for the study. The post Atai May Step Away from Ketamine Study After Releasing Positive Results appeared...
Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The post atai Life...